Tetragenetics is an innovative biotech company specializing in the discovery and development of novel therapeutics targeting autoimmune diseases and pain. The company leverages the unique capabilities of the protozoa Tetrahymena thermophila to produce recombinant proteins, which are crucial for the discovery of new antibody therapeutics aimed at membrane proteins involved in various human diseases. Tetragenetics operates in the biotech and pharmaceutical markets, serving clients such as pharmaceutical companies, research institutions, and biotech firms. The business model revolves around producing and supplying high-quality recombinant human ion channel proteins, which are used as antigens in antibody discovery programs and for structure determination to support the rational design of small molecule drugs. Revenue is generated through the sale of these proteins and through partnerships and collaborations with other biotech and pharmaceutical companies.

Keywords: biotech, autoimmune disease, pain therapeutics, recombinant proteins, ion channels, antibody discovery, Tetrahymena thermophila, membrane proteins, drug development, pharmaceutical.